4 November 2022
Reduction of prices of medicines leads to savings of at least 250 million Swiss francs from 2020 to 2022
The Federal Office of Public Health (FOPH) has reduced the prices of a good 300 medicines by an average of 10% as part of its triennial review for 2022. Savings of at least 60 million Swiss francs are expected as a result of this review. Thanks to the 2020 to 2022 review period, the FOPH thus expects savings of at least 250 million Swiss francs.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar